Advanced Enzyme Technologies Limited

NSEI:ADVENZYMES Stock Report

Market Cap: ₹39.8b

Advanced Enzyme Technologies Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mukund Kabra

Chief executive officer

₹29.3m

Total compensation

CEO salary percentage22.9%
CEO tenure25.3yrs
CEO ownership1.6%
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Recent updates

After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 18
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut

Feb 03
I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut

What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?

Jan 19
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?

What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?

Dec 28
What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?

Dec 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?

Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?

Nov 28
Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?

Nov 20
Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?

Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today

Nov 05
Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today

What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition

Oct 21
What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition

CEO Compensation Analysis

How has Mukund Kabra's remuneration changed compared to Advanced Enzyme Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹1b

Jun 30 2024n/an/a

₹1b

Mar 31 2024₹29m₹7m

₹1b

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹1b

Jun 30 2023n/an/a

₹1b

Mar 31 2023₹24m₹6m

₹1b

Dec 31 2022n/an/a

₹979m

Sep 30 2022n/an/a

₹960m

Jun 30 2022n/an/a

₹995m

Mar 31 2022₹22m₹6m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹21m₹5m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹19m₹5m

₹1b

Dec 31 2019n/an/a

₹1b

Sep 30 2019n/an/a

₹1b

Jun 30 2019n/an/a

₹1b

Mar 31 2019₹17m₹4m

₹1b

Dec 31 2018n/an/a

₹1b

Sep 30 2018n/an/a

₹1b

Jun 30 2018n/an/a

₹1b

Mar 31 2018₹15m₹4m

₹901m

Compensation vs Market: Mukund's total compensation ($USD343.19K) is about average for companies of similar size in the Indian market ($USD268.22K).

Compensation vs Earnings: Mukund's compensation has increased by more than 20% in the past year.

CEO

Mukund Kabra (52 yo)

25.3yrs

Tenure

₹29,259,649

Compensation

Mr. Mukund Madhusudan Kabra serves as a Whole Time Director at Advanced Enzyme Technologies Ltd. since April 1, 2009 and also served as its Director since September 4, 1999. Mr. Kabra began at the junior-m...

Board Members

NamePositionTenureCompensationOwnership
Mukund Kabra
Whole Time Director25.3yrs₹29.26m1.63%
₹ 647.9m
Nitin Deshmukh
Independent Director2.4yrs₹620.00kno data
Sunny Sharma
Non-Executive Director5.1yrs₹350.00kno data
Pramod Kasat
Independent Non-Executive Director8yrs₹1.18m0.0045%
₹ 1.8m
Vasant Rathi
Chairman31.8yrs₹1.13m38.57%
₹ 15.3b
Rasika Rathi
Additional Non-Executive Director5.9yrs₹260.00k2.38%
₹ 947.4m
Vinodkumar Jajoo
Independent Director5.8yrs₹1.19mno data
Rajshree Patel
Independent Director4.5yrs₹720.00kno data
Vandana Tilak
Independent Director1.4yrsno datano data

5.8yrs

Average Tenure

55yo

Average Age

Experienced Board: ADVENZYMES's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:56
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Advanced Enzyme Technologies Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nandan ChakrabortyAxis Capital Limited
null nullDBS Bank Ltd
Dhananjay SinhaEmkay Global Financial Services Ltd.